DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ovarian dysgenesis 8 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian dysgenesis 8 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian dysgenesis 8 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
estrogen receptor 2 (ESR2) — ESR2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3-fluoro-4-hydroxyphenyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1YYE · 2.03 Å · ligand 3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE (196). Experimental structure, not a prediction.
What the evidence adds up to
A 2012 genome-wide linkage study in one large consanguineous Middle-Eastern family with premature ovarian failure (POF) identified two novel loci on chromosome 7 (7p21.1-15.3 and 7q21.3-22.2) with a maximum LOD score of 3.26. Sequencing of three candidate genes within the largest region — DLX5, DLX6 and DSS1 — found no causal mutations. The study notes that about 90% of POF patients still have no known genetic cause.
A 2006 review describes orthotopic ovarian transplant as still in its infancy, with three surgical techniques reported in three cases. A 2025 narrative review on diminished ovarian reserve (DOR) states that stem cell transplantation, in vitro activation, and platelet-rich plasma injection have shown some positive results but that more high-quality studies are needed before broader clinical application. The same review notes that DOR inevitably occurs during ovarian fragment transplantation.
A 2017 review on gonadotropin-releasing hormone analogues for preventing chemotherapy-induced POF in breast cancer patients reports that temporary ovarian suppression with LHRHa showed effectiveness in reducing treatment-related POF in several randomised trials, but its use as a standard procedure remains under debate. The review also states that embryo and oocyte cryopreservation are the standard fertility preservation methods but do not protect whole ovarian function or prevent POF and its side effects.
A 2025 review on drug repositioning for ovarian cancer therapy describes in vitro experiments across diverse cancer cell lines validated through preclinical in vivo models, and mentions potential synergies with other agents. No specific drugs, response rates, or survival data from repositioning trials are reported in the provided abstracts. A 2007 session abstract notes that ovarian dysplasia in BRCA1/BRCA2 germline mutation carriers is considered a preneoplastic phenotype, and suggests a possible relationship between fertility drugs (especially clomifene) and borderline ovarian tumours. What remains missing for ovarian dysgenesis specifically are large, well-funded genetic studies in diverse populations, prospective trials of any therapeutic approach (transplant, stem cells, hormone suppression) in patients with defined genetic causes, and any randomised controlled data on drug repurposing for this condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PLoS ONE · 2012 · 50 citations · open access
Genome-Wide Linkage in a Highly Consanguineous Pedigree Reveals Two Novel Loci on Chromosome 7 for Non-Syndromic Familial Premature Ovarian Failure
AbstractBACKGROUND: The human condition known as Premature Ovarian Failure (POF) is characterized by loss of ovarian function before the age of 40. A majority of POF cases are sporadic, but 10-15% are familial, suggesting a genetic origin of the disease. Although several causal mutations have been identified, the etiology of POF is still unknown for about 90% of the patients. METHODOLOGY/PRINCIPAL FINDINGS: We report a genome-wide linkage and homozygosity analysis in one large consanguineous Middle-Eastern POF-affected family presenting an autosomal recessive pattern of inheritance. We identified two regions with a LOD(max) of 3.26 on chromosome 7p21.1-15.3 and 7q21.3-22.2, which are supported as candidate regions by homozygosity mapping. Sequencing of the coding exons and known regulatory sequences of three candidate genes (DLX5, DLX6 and DSS1) included within the largest region did not reveal any causal mutations. CONCLUSIONS/SIGNIFICANCE: We detect two novel POF-associated loci on human chromosome 7, opening the way to the identification of new genes involved in the control of ovarian development and function.
Pediatric Transplantation · 2006 · 19 citations · open access
Orthotopic ovarian transplant – review and three surgical techniques
AbstractTransplantation of organs is a rapidly expanding faculty of medicine. While the solid organ transplantation has grown by leaps and bounds, ovarian transplantation is still in its infancy. Although recent interest has been generated for preservation of fertility in cancer therapy patients, other indications have emerged. Ovarian dysgenesis with missing normal ovarian complement and premature ovarian failure has come in the forefront. Three cases of orthotopic ovarian transplant with different surgical techniques have been described along with a brief overview.
Minerva Obstetrics and Gynecology · 2017 · 9 citations
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients
AbstractSince the survival of patients with cancer has significantly improved, chemotherapy-related premature ovarian failure (POF) in young cancer survivors has become a major issue in oncology. POF is associated with several health-related negative consequences, including menopausal symptoms, increased risk of cardiovascular diseases, osteoporosis, sexual dysfunction, and infertility. According to the major international guidelines, embryo/oocyte cryopreservation are the standard procedures for fertility preservation in young cancer women. However, these techniques do not protect the whole ovarian function from the gonadotoxicity of anticancer therapies; indeed, they can only preserve fertility without preventing POF and related side effects. In recent years, temporary ovarian suppression during chemotherapy with lutenising hormone-releasing hormone analogues (LHRHa) has emerged as an option to preserve both gonadal function and fertility. Despite temporary ovarian suppression with LHRHa showed to be an effective strategy to reduce the risk of treatment-related POF in several randomized clinical trials, its use as a standard procedure is still under debate. The present review will encompass the current evidences and controversies on the efficacy and safety of ovarian protection with LHRHa during chemotherapy for preservation of ovarian function and fertility in breast cancer patients, in light of the new data published.
Frontiers in Oncology · 2025 · 7 citations · open access
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments
AbstractDrug repositioning, the practice of identifying novel applications for existing drugs beyond their originally intended medical indications, stands as a transformative strategy revolutionizing pharmaceutical productivity. In contrast to conventional drug development approaches, this innovative method has proven to be exceptionally effective. This is particularly relevant for cancer therapy, where the demand for groundbreaking treatments continues to grow. This review focuses on drug repositioning for ovarian cancer treatment, showcasing a comprehensive exploration grounded in thorough in vitro experiments across diverse cancer cell lines, which are validated through preclinical in vivo models. These insights not only shed light on the efficacy of these drugs but also expand in potential synergies with other pharmaceutical agents, favoring the development of cost-effective treatments for cancer patients.
Journal of Menopausal Medicine · 2025 · 4 citations · open access
Diminished Ovarian Reserve: A Narrative Review of Etiologies and Possible Therapeutic Approaches
AbstractDiminished ovarian reserve (DOR) occurs unintentionally during treatment or spontaneously. Despite its significant clinical manifestations, such as infertility and early menopause, and its high prevalence, most studies on DOR have focused on premature ovarian insufficiency, and reviews specifically addressing DOR remain scarce. This narrative review aims to provide insight into the diverse etiologies of DOR while discussing promising therapeutic approaches. Iatrogenic DOR can occur during chemotherapy, pelvic radiation, and ovarian surgery. Spontaneous DOR may result from ovarian tumors as well as idiopathic or genetic causes. DOR also inevitably occurs during ovarian fragment transplantation. Stem cell transplantation, in vitro activation, and platelet-rich plasma injection have shown some positive results as therapeutic approaches to DOR; however, more high-quality studies are needed to establish their broader applications in clinical practice.
Human Reproduction · 2007 · 0 citations · open access
Session 48: ART - IUI
Abstract3. Because of the well-known high risks of ovarian cancer and the presence of ovarian dysplasia in germ line mutations in BRCA1 or BRCA2, Ovarian dysplasia in this group of prophylactic oophorectomy would be the precursor to ovarian carcinoma ( a preneoplastic phenotype ). Furthermore, several epidemiologic studies have suggested a possible relationship between fertility drugs use and Borderline ovarian tumours. The different features of dysplasia between ovulation group and prophylactic oophorectomy group could confirm that ovulation induction therapy and mainly clomifene could lead to borderline tumours. 4. The late occurrence of an ovarian cyst after IVF must be lead to a strict surgical approach.
Clinical Theriogenology · 2025 · 0 citations · open access
Foreword
AbstractIt is our pleasure to bring you another special edition of Clinical Theriogenology. This edition focuses on Therapeutics in Theriogenology including estrus manipulation and diagnosis and treatment of selective ovarian diseases across species. This issue includes eight review articles contributed by several authors. We thank our colleagues for contributing to this special issue and hope you enjoy this collection of manuscripts.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
